AU2003267361A1 - Orthopoxvirus antigens and use thereof - Google Patents
Orthopoxvirus antigens and use thereofInfo
- Publication number
- AU2003267361A1 AU2003267361A1 AU2003267361A AU2003267361A AU2003267361A1 AU 2003267361 A1 AU2003267361 A1 AU 2003267361A1 AU 2003267361 A AU2003267361 A AU 2003267361A AU 2003267361 A AU2003267361 A AU 2003267361A AU 2003267361 A1 AU2003267361 A1 AU 2003267361A1
- Authority
- AU
- Australia
- Prior art keywords
- orthopoxvirus
- antigens
- orthopoxvirus antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700629 Orthopoxvirus Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/065—Poxviridae, e.g. avipoxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10242318A DE10242318A1 (en) | 2002-09-12 | 2002-09-12 | Orthopox virus antigens and their use |
DE10242318.0 | 2002-09-12 | ||
EP20020022252 EP1398380A1 (en) | 2002-09-12 | 2002-10-02 | Orthopoxvirus antigens and use thereof |
EP02022252.7 | 2002-10-02 | ||
PCT/EP2003/010226 WO2004024756A2 (en) | 2002-09-12 | 2003-09-12 | Orthopoxvirus antigens and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003267361A8 AU2003267361A8 (en) | 2004-04-30 |
AU2003267361A1 true AU2003267361A1 (en) | 2004-04-30 |
Family
ID=31995061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003267361A Abandoned AU2003267361A1 (en) | 2002-09-12 | 2003-09-12 | Orthopoxvirus antigens and use thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003267361A1 (en) |
WO (1) | WO2004024756A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067535B2 (en) | 2003-01-24 | 2011-11-29 | The University Of Massachusetts | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes |
EP1624890B1 (en) | 2003-01-24 | 2011-07-13 | University Of Massachusetts Medical Center | Identification of vaccinia virus dominant t cell epitopes |
ITRM20030386A1 (en) * | 2003-08-05 | 2005-02-06 | Istituto Naz Per Le Malattie Infettive Lazz | METHOD AND DIAGNOSTIC TESTS BASED ON THE CITOFLUORIMETRIC ANALYSIS OF ANTIGEN-SPECIFIC T LYMPHOCYTES. |
CN107735103B (en) | 2015-02-25 | 2022-05-27 | 纪念斯隆-凯特琳癌症中心 | Use of inactivated non-replicative modified vaccinia virus ankara (MVA) as a sole immunotherapy of solid tumors or in combination with immune checkpoint blockers |
KR20180006916A (en) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | Use of MVA or MVA delta E3L as an immunotherapeutic agent for solid tumors |
SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
CA3015818A1 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mva.delta.e3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
AU2019339535A1 (en) | 2018-09-15 | 2021-04-08 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
CN117756949B (en) * | 2024-02-21 | 2024-10-15 | 中国人民解放军军事科学院军事医学研究院 | Orthopoxvirus fusion antigen and its application |
-
2003
- 2003-09-12 AU AU2003267361A patent/AU2003267361A1/en not_active Abandoned
- 2003-09-12 WO PCT/EP2003/010226 patent/WO2004024756A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2003267361A8 (en) | 2004-04-30 |
WO2004024756A2 (en) | 2004-03-25 |
WO2004024756A3 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003299778A1 (en) | Antibodies against gpr64 and uses thereof | |
AU2002357643A1 (en) | The human mob-5 (il-24) receptors and uses thereof | |
AU2003272187A1 (en) | Novel nanoparticles and use thereof | |
AU2002315389A1 (en) | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof | |
AU2002314433A1 (en) | Ephrin-tie receptor materials and methods | |
AU2003241477A1 (en) | Nanoparticulate polycosanol formulations and novel polycosanol combinations | |
AU2002315388A1 (en) | Novel phenylamino-pyrimidines and uses thereof | |
AU2002364051A1 (en) | Anti-cancer combination and use thereof | |
AU2003296369A1 (en) | Imminoamines and preparation thereof | |
AU2003224313A1 (en) | Mycobacterial antigens and uses thereof | |
AU2002343724A1 (en) | Adhesive and use thereof | |
AU2003267361A1 (en) | Orthopoxvirus antigens and use thereof | |
AU2003298129A1 (en) | Floor-furnace chimney and the use thereof | |
AU2003219093A1 (en) | Anti-hpv-16 e7 antibodies and their use | |
AU2003281691A1 (en) | Furoisoquinoline derivative and use thereof | |
AU2002312373A1 (en) | Structural and cytoskeleton-associated proteins | |
AU2003231827A1 (en) | Pseudo-tissues and uses thereof | |
AU2003207628A1 (en) | Structural and cytoskeleton-associated proteins | |
AU2003302173A1 (en) | Spirotetrathiocarbamates and spirooxothiocarbamates | |
AU2003280992A1 (en) | Novel proteins and use thereof | |
AU2003263329A1 (en) | Foxp2 and uses thereof | |
AU2003263326A1 (en) | Foxp1 and uses thereof | |
AU2003228397A1 (en) | HAUSP-p53 INTERACTION AND USES THEREOF | |
AU2003292774A1 (en) | Novel proteins and use thereof | |
AU2003216442A1 (en) | Enkurin and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |